Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Gains from Investment Securities (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Gains from Investment Securities for 8 consecutive years, with $3000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities fell 87.19% to $3000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$877000.0, a 3843.54% decrease, with the full-year FY2024 number at $376551.0, up 7.69% from a year prior.
  • Gains from Investment Securities was $3000.0 for Q3 2025 at Precision Biosciences, up from $955.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $14.9 million in Q3 2021 to a low of -$626000.0 in Q4 2023.
  • A 5-year average of $2.4 million and a median of $13213.5 in 2024 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: surged 51776.4% in 2022, then tumbled 1204.17% in 2023.
  • Precision Biosciences' Gains from Investment Securities stood at $600000.0 in 2021, then crashed by 108.0% to -$48000.0 in 2022, then crashed by 1204.17% to -$626000.0 in 2023, then surged by 160.15% to $376551.0 in 2024, then crashed by 99.2% to $3000.0 in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Gains from Investment Securities are $3000.0 (Q3 2025), $955.0 (Q1 2025), and $376551.0 (Q4 2024).